
|Articles|August 12, 2014
- Gastrointestinal Cancers (Issue 2)
- Volume 2
- Issue 1
Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC
Author(s)Paulo Marcelo Hoff, MD, PhD, FACP
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Advertisement
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Learn about adverse events associated with regorafenib for mCRC > >
Articles in this issue
over 11 years ago
An Analysis of Bevacizumab or Cetuximab for CRCover 11 years ago
The Importance of Testing for BRAF Status in CRC Patientsover 11 years ago
Proactive Management of Regorafenib-Associated AEsover 11 years ago
Survival Benefit Confirmed With Palliative Resection in mCRCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5










































